Cargando…

Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction

BACKGROUND: Fibroblast growth factor-23 (FGF23) has been associated to left ventricular (LV) hypertrophy and heart failure (HF) severity. We aimed to investigate the clinical correlates and prognostic value of intact FGF23 (iFGF23) in HF patients. METHODS: Patients with stable HF and left ventricula...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vergaro, Giuseppe, Del Franco, Annamaria, Aimo, Alberto, Gentile, Francesco, Castiglione, Vincenzo, Saponaro, Federica, Masotti, Silvia, Prontera, Concetta, Fusari, Niccolò, Emdin, Michele, Passino, Claudio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474676/ https://www.ncbi.nlm.nih.gov/pubmed/37658340 http://dx.doi.org/10.1186/s12872-023-03441-2

Ejemplares similares

The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction
por: Aimo, Alberto, et al.
Publicado: (2021)

Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction
por: Castiglione, Vincenzo, et al.
Publicado: (2023)

Biomarkers for the diagnosis and management of heart failure
por: Castiglione, Vincenzo, et al.
Publicado: (2021)

Central and Obstructive Apneas in Heart Failure With Reduced, Mid-Range and Preserved Ejection Fraction
por: Borrelli, Chiara, et al.
Publicado: (2019)

Renin profiling predicts neurohormonal response to sacubitril/valsartan
por: Vergaro, Giuseppe, et al.
Publicado: (2020)

Noncardiac Versus Cardiac Mortality in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction
por: Vergaro, Giuseppe, et al.
Publicado: (2019)

Prognostic value of reverse remodelling criteria in heart failure with reduced or mid‐range ejection fraction
por: Aimo, Alberto, et al.
Publicado: (2021)

Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient
por: Vergaro, Giuseppe, et al.
Publicado: (2021)

Amyloid Deposits and Fibrosis on Left Ventricular Endomyocardial Biopsy Correlate With Extracellular Volume in Cardiac Amyloidosis
por: Pucci, Angela, et al.
Publicado: (2021)

Biomarkers of HFpEF: Natriuretic Peptides, High-Sensitivity Troponins and Beyond
por: Morfino, Paolo, et al.
Publicado: (2022)

Monoclonal antibodies and amyloid removal as a therapeutic strategy for cardiac amyloidosis
por: Emdin, Michele, et al.
Publicado: (2023)

Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin
por: Aimo, Alberto, et al.
Publicado: (2022)

Vericiguat for Heart Failure with Reduced Ejection Fraction
por: Lombardi, Carlo Mario, et al.
Publicado: (2021)

Atrial amyloidosis: mechanisms and clinical manifestations
por: Vergaro, Giuseppe, et al.
Publicado: (2022)

Intracoronary Delivery of Mitochondria to Prevent Ischemia–Reperfusion Injury: Challenging Pathway From Bench to Bedside
por: Aimo, Alberto, et al.
Publicado: (2020)

Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targets
por: Fabiani, Iacopo, et al.
Publicado: (2020)

Role of Imaging in Cardiomyopathies
por: Castiglione, Vincenzo, et al.
Publicado: (2023)

Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers
por: Chianca, Michela, et al.
Publicado: (2022)

Current and emerging drug targets in heart failure treatment
por: Ghionzoli, Nicolò, et al.
Publicado: (2021)

Molecular Autopsy of Sudden Cardiac Death in the Genomics Era
por: Castiglione, Vincenzo, et al.
Publicado: (2021)

Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy
por: Morfino, Paolo, et al.
Publicado: (2023)

Fibroblast Growth Factor‐23 and Heart Failure With Reduced Versus Preserved Ejection Fraction: MESA
por: Almahmoud, Mohamed Faher, et al.
Publicado: (2018)

Abdominal Fat Biopsy for the Diagnosis of Cardiac Amyloidosis
por: Aimo, Alberto, et al.
Publicado: (2020)

Valve disease in cardiac amyloidosis: an echocardiographic score
por: Aimo, Alberto, et al.
Publicado: (2023)

The Journey of Human Transthyretin: Synthesis, Structure Stability, and Catabolism
por: Sanguinetti, Chiara, et al.
Publicado: (2022)

The Prognostic Value of Anemia in Patients with Preserved, Mildly Reduced and Recovered Ejection Fraction
por: Pintér, Anita, et al.
Publicado: (2022)

Subclinical cardiac damage in cancer patients before chemotherapy
por: Fabiani, Iacopo, et al.
Publicado: (2021)

Cardiovascular toxicity from therapies for light chain amyloidosis
por: Morfino, Paolo, et al.
Publicado: (2023)

Sympathetic activation in heart failure with reduced and mildly reduced ejection fraction: the role of aetiology
por: Urbancsek, Réka, et al.
Publicado: (2021)

The Prescription Pattern of Heart Failure Medications in Reduced, Mildly Reduced, and Preserved Ejection Fractions
por: Rastogi, Tripti, et al.
Publicado: (2022)

Fibroblast Growth Factor 23 and Risk of New Onset Heart Failure With Preserved or Reduced Ejection Fraction: The PREVEND Study
por: Binnenmars, S. Heleen, et al.
Publicado: (2022)

Risk stratification in heart failure with mild reduced ejection fraction
por: Magrì, Damiano, et al.
Publicado: (2020)

Heart failure with mid-range or mildly reduced ejection fraction
por: Savarese, Gianluigi, et al.
Publicado: (2021)

Combined Neuro-Humoral Modulation and Outcomes in Patients with Chronic Heart Failure and Mildly Reduced or Preserved Ejection Fraction
por: Gori, Mauro, et al.
Publicado: (2022)

Heart failure with mildly reduced ejection fraction: retrospective study of ejection fraction trajectory risk
por: Miller, Robert J.H., et al.
Publicado: (2022)

Long-Term Outcomes of Heart Failure Patients With Preserved, Mildly Reduced, and Reduced Ejection Fraction
por: Nagata, Takuya, et al.
Publicado: (2023)

Total 25-Hydroxyvitamin D Is an Independent Marker of Left Ventricular Ejection Fraction in Heart Failure with Reduced and Mildly Reduced Ejection Fraction
por: Szabo, Timea Magdolna, et al.
Publicado: (2023)

Serum intact fibroblast growth factor 23 in healthy paediatric population
por: Stanczyk, Malgorzata, et al.
Publicado: (2021)

Central Apneas Are More Detrimental in Female Than in Male Patients With Heart Failure
por: Gentile, Francesco, et al.
Publicado: (2022)

Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction
por: Talha, Khawaja M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_j60qdb6b0eak2gt7cqam3vh2tc